Myriad Genetics (MYGN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
February 8, 2017 9:12 AM ESTPiper Jaffray analyst William Quirk reaffirms Neutral rating and raises price target on Myriad Genetics (NASDAQ: MYGN) to $22 (from $21), noting 2017 fiscal second quarter numbers for the company were strong, but near-term risks remain.
Quirk comments, "MYGN is up ~15% in aftermarket trading after... More
Ladenburg Thalmann Upgrades Myriad Genetics (MYGN) to Neutral
February 8, 2017 6:42 AM ESTLadenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $15.40 yesterday.
... More


